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In	 the	 absence	 of	 further	 evidence,	 the	 recommendation	 about	 its	 use	 should	 be	
reconsidered.
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1  | INTRODUCTION










Two	different	 systems	have	been	proposed	 to	classify	EH:	 the	
World	Health	Organization	(WHO)	system	and	the	endometrial	in‐
traepithelial	neoplasia	(EIN)	system.2,3
The	 WHO	 system	 distinguishes	 “EH	 without	 atypia”	 (benign)	






“morphometric	D‐score,”	which	 subdivides	EH	 into	 “high/interme‐






differential	 diagnosis	 between	 benign	 and	 premalignant	 EH.	 The	
WHO	system	is	recommended	by	the	Royal	College	of	Obstetricians	
and	 Gynaecologists,	 whereas	 the	 EIN	 system	 is	 recommended	
by	 the	 American	 College	 of	 Obstetricians	 and	 Gynecologists.4,5 
Nonetheless,	 histologic	 classifications	may	 be	 affected	 by	 several	
problems,	 such	 as	 low	 reproducibility,	 tissue	 inadequacy,	 artefact	
changes,	or	ambiguous	features.3,6
To	 improve	 the	 reliability	 of	 the	 differential	 diagnosis,	 several	
diagnostic	markers	have	been	proposed.	Great	emphasis	has	been	
given	 to	 the	 loss	 of	 expression	 of	 the	 tumor	 suppressor	 protein	
phosphatase	 and	 tensin	homolog	 (PTEN),2,7	 because	 the	mutation	
of	 PTEN	 is	 the	 most	 common	 molecular	 alteration	 found	 in	 en‐






















data	 analysis.	 Disagreements	 were	 resolved	 by	 discussion	 with	 a	
third	reviewer	(GS).
The	study	was	reported	following	the	Preferred	Reporting	Item	
for	 Systematic	 Reviews	 and	Meta‐analyses	 (PRISMA)	 statement11 
and	 the	 Synthesizing	 Evidence	 from	 Diagnostic	 Accuracy	 Tests	
(SEDATE)	guideline.12
Searches	 were	 conducted	 using	 MEDLINE,	 EMBASE,	 Web	 of	




SubHeading	 (MeSH)	vocabulary:	 “endometrial	hyperplasia”;	 “endo‐
metrial	intraepithelial	neoplasia”;	“EIN”;	“precancer”;	“premalignant”;	
“precursor”;	 “PTEN”;	 “phosphatase	 and	 tensin	homolog”;	 “marker”;	
“biomarker”;	 “diagnosis”	 “immunohistochemistry”;	 “immunohisto‐
chemical”.	Review	of	articles	also	included	the	abstracts	of	all	refer‐
ences	retrieved	from	the	search.







metrial	 hyperplasia.	Hence,	 its	 recommended	use	 should	
be reconsidered.
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All	 peer‐reviewed	 retrospective	 or	 prospective	 studies	 assess‐
ing	 the	 immunohistochemical	 expression	 of	 PTEN	 on	 histological	
















to	confirm	the	 index	diagnosis);	 (4)	 flow	and	timing	 (low	risk	 if	 the	
latency	time	between	 index	and	reference	standard	did	not	affect	
the	results,	 if	all	patients	were	assessed	with	 the	same	tests,	 if	all	
patients	were	 assessed	with	 both	 index	 and	 reference	 standards).	
Review	 authors’	 judgments	 were	 categorized	 as	 “low	 risk,”	 “high	
risk,”	or	“unclear	risk”	of	bias.
Data	 from	 each	 eligible	 study	 were	 extracted	 without	 modi‐
fication	of	 the	original	 data.	 Two‐by‐two	 contingency	 tables	were	
prepared	 for	 each	 study,	 reporting	 two	 dichotomous	 qualitative	
variables:










1.	 for	 the	 studies	 dichotomizing	 PTEN	 expression	 (positive	 vs	
negative)	 independently	 from	 distribution	 and	 intensity	 of	 ex‐










or	 complex)	 was	 considered	 as	 “precancer,”	 while	 EH	 without	
atypia	 (simple	 or	 complex)	 was	 considered	 as	 “benign”;
2.	 for	the	studies	using	the	EIN	classification,	endometrial	intraepi‐
thelial	neoplasia	or	high/intermediate‐risk	EH	 (D	≤	1)	were	con‐
sidered	 as	 “precancer,”	 while	 benign	 EH	 or	 low‐risk	 EH	 (D	<	1)	
were	considered	as	“benign”;
3.	 hyperproliferative	conditions	caused	by	unopposed	action	of	es‐








Sensitivity,	 specificity,	 positive	 likelihood	 ratio	 (LR+),	 negative	





insignificant	 for	 I2	<	25%,	 low	 for	 I2	<	50%,	moderate	 for	 I2	<	75%,	
and	high	for	I2	≥	75%.
Area	under	the	curve	(AUC)	was	calculated	on	summary	receiver	
operating	 characteristic	 (SROC)	 curves.	 The	 diagnostic	 usefulness	
was	 considered	 absent	 for	 AUC	≤	0.5,	 low	 for	 0.5	<	AUC	≤	0.75,	
moderate	for	0.75	<	AUC	≤	0.9,	high	for	0.9	<	AUC	<	0.97,	and	very	
high	for	AUC	≥	0.97.
As	 additional	 analysis,	we	performed	a	 subgroups	 analysis,	 as‐
sessing	sensitivity,	 specificity,	LR+,	LR−,	DOR,	and	AUC	separately	
for	the	two	subgroups.





We	 identified	 635	 articles	 through	 database	 searching	 and	 13	





meta‐analysis.	Details	 about	 the	whole	process	of	 study	 selection	
are	shown	in	Figure	1.
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Twenty‐seven	 observational	 studies	were	 included	 in	 the	 sys‐
tematic	review:7,15‐40	19	adopted	the	WHO	classification	and	eight	
adopted	 the	 EIN	 classification.	 A	 total	 of	 1736	 cases	 of	 EH	were	
included;	 847	 (48.8%)	 EH	were	 classified	 as	 “precancer”	 and	 889	
(51.2%)	as	“benign.”	PTEN	loss	was	observed	in	443	of	847	(52.3%)	
premalignant	EH	and	299	of	889	(33.6%)	benign	EH.














particular,	 for	 the	 “patient	 selection”	 domain,	 three	 studies	 were	

































the	WHO	system	were	 included	 in	 first	 subgroup;	 295	 (31.6%)	 of	
total	EH	were	premalignant	and	639	(68.4%)	were	benign.
Pooled	sensitivity	and	specificity	were	59%	(95%	CI	53%‐65%)	
and	 65%	 (95%	 CI	 62%‐69%),	 respectively,	 with	 pooled	 LR+	 and	





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































phatase	 activity,	 which	 induces	 cell	 cycle	 arrest,	 upregulates	
AKT‐dependent	 pro‐apoptotic	 mechanisms	 and	 downregulates	
Bcl‐2‐dependent	 anti‐apoptotic	 mechanisms,	 acting	 in	 opposition	
TA B L E  2  Methods	for	immunohistochemistry	in	each	included	study
Year First author (ref)
Antibody Incubation
Vendor Clone Time Temperature Dilution
2000 Mutter	7 Not	reported 6H2.1 1	h Room	temperature 1:100
2001 Mutter	15 Cascade	Biosciences 6H2.1 Overnight 4°C 1:300
2003 Ørbo 16 Santa	Cruz	
Biotechnology
A2B1 30 min Room	temperature 1:50
2005 Baak	17 Cascade	Biosciences 6H2.1 30 min Not	reported 1:300
2006 Cirpan	18 Novocastra 28H6 30 min Not	reported Not	reported
McCampbell	19 Cascade	Biosciences 6H2.1 Overnight 4°C 1:50
2007 Kapucuoglu	20 LabVision 17.A 1	h Not	reported 1:50
Minaguchi	21 Santa	Cruz	
Biotechnology
A2B1 Overnight 4°C 1:50
Norimatsu	22 Cascade	Biosciences 6H2.1 Not	reported Not	reported 1:100
2008 Chen	23 Antibody	Diagnostica Not	reported 1	h Not	reported 1:60
Lacey	24 Cascade	Biosciences 6H2.1 Overnight 4°C 1:300
Tantbirojn	25 Cascade	Biosciences 6H2.1 1	h Room	temperature 1:100
2009 Abd	El‐Masqoud	26 LabVision 28H6 Not	reported Not	reported 1:100
Sarmadi	27 Zymed	Laboratories Polyclonal 60 min Not	reported 1:100
2010 Monte	28 Dako 6H2.1 Overnight 4°C 1:100
Pavlakis	29 Cascade	Biosciences 6H2.1 Overnight 4°C 1:300
Xiong 30 Maixin	Bio Not	reported Not	reported Not	reported Not	reported
2011 Pieczynska	31 Novocastra Not	reported 1.5	h Room	temperature 1:800
Rao 32 Biogenex 28H6 Not	reported Not	reported Not	reported
2012 Feng	33 Antibody	Diagnostica Not	reported 1	h 37°C 1:60
Lee	34 Cell	Signaling	Technology 138G6 Not	reported Not	reported 1:100
Robbe 35 Not	reported Not	reported 30 min Room	temperature Not	reported
Upson	36 Cascade	Biosciences 6H2.1 40 min Room	temperature 1:100
2013 Huang	37 Dako 6H2.1 Not	reported Not	reported 1:100
2014 Shawana	38 Millipore 6H2.1 1	h Room	temperature 1:50
2015 Ayhan	39 Dako 6H2.1 Not	reported Not	reported 1:100
Berg	40 Cell	Signaling #9188 Overnight 4°C 1:100
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to	phosphatidylinositol	3‐kinase	(PI3K).	Moreover,	PTEN	has	also	a	
protein	phosphatase	activity,	which	 is	 involved	 in	 the	 inhibition	of	
focal	adhesion	formation,	cell	spread,	and	growth‐factor‐stimulated	
mitogen‐activated	protein	kinase	(MAPK)	signaling.41





of	 PTEN	 has	 a	 low	 diagnostic	 usefulness,	 as	 demonstrated	 by	 an	
AUC	<	0.75	(0.657).








However,	 a	 suboptimal	 sensitivity	might	be	expected,	because	
not	 all	 endometrioid	 adenocarcinomas	 or	 their	 precursor	 lesions	
have	underlying	mutations	of	the	PTEN	gene.8,9
Concerning	 the	 low	 specificity,	 a	 possible	 cause	may	be	 that	 a	
loss	 of	 PTEN	expression	 does	 not	 necessarily	 indicate	 a	monoclo‐
nal	 lesion.	 In	 fact,	Yilmaz	et	al	observed	PTEN	 loss	using	 immuno‐





In	 the	WHO	 subgroup,	 higher	 sensibility	 and	DOR,	 and	 lower	
specificity,	LR+,	and	LR−,	were	found	when	compared	with	the	EIN	





























F I G U R E  3  Forest	plots	of	individual	studies	and	pooled	sensitivity	(A),	specificity	(B),	positive	likelihood	ratio	(C),	negative	likelihood	
ratio	(D),	and	diagnostic	odds	ratio	(E)	of	PTEN	immunohistochemical	assessment	in	differential	diagnosis	between	benign	and	premalignant	
endometrial	hyperplasia,	with	summary	receiver	operating	characteristic	curves	(F)	[Color	figure	can	be	viewed	at	wileyonlinelibrary.com]
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variability	may	explain	the	high	heterogeneity	observed	for	sensitiv‐
ity	and	specificity	analysis.
Concerns	 about	 the	 index	 text	 regard	 the	 lack	 of	 standard‐
ized	 and	 objective	 criteria	 for	 interpreting	 PTEN	 immunostaining.	






























In	our	opinion,	 further	 studies	 in	 this	 field	 should	 improve	 the	
reliability	of	both	the	index	test	and	the	reference	standard.
The	reliability	of	the	index	test	might	be	improved	by	standard‐




6H21	was	used	in	the	study	showing	the	highest	DOR,38 as well as in 
the	one	showing	the	lowest	DOR.29	A	study	published	in	2011	sug‐
gested	the	clone	138G6	to	be	the	most	reliable.48	In	our	systematic	








above,	 it	 is	probable	that	 the	diagnostic	usefulness	of	PTEN	alone	
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might	be	fair	at	best,	even	with	optimized	criteria.	Further	studies	




Although	 a	 loss	 of	 PTEN	 expression	 was	 associated	 with	 endo‐
metrial	precancer,	 immunohistochemistry	 for	PTEN	showed	a	 low	
diagnostic	usefulness	 in	the	differential	diagnosis	between	benign	
and	premalignant	EH,	independently	from	the	histologic	classifica‐
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